ResMed Inc. — Form 10-K Summary
Period and context: The supplied filing is ResMed’s annual report for the fiscal year ended June 30, 2014, filed August 8, 2014—not a report for calendar 2013 Q4. The filing includes unaudited quarterly data for fiscal Q4, ended June 30, 2014. ResMed develops and sells devices and related products for sleep-disordered breathing and other respiratory disorders, including CPAP flow generators, masks, diagnostics and ventilators. It reports one operating segment and sells in about 100 countries.
Financial performance and position
| Metric | FY2014 | FY2013 |
|---|---|---|
| Revenue | $1,555.0 million | $1,514.5 million |
| Gross profit / margin | $989.8 million / 63.7% | $940.7 million / 62.1% |
| Operating income | $405.1 million | $354.8 million |
| Net income | $345.3 million | $307.1 million |
| Diluted EPS | $2.39 | $2.10 |
| Cash from operations | $391.3 million | $402.8 million |
| Cash and cash equivalents at year-end | $905.7 million | $876.0 million |
| Working capital | $1,286.7 million | $874.8 million |
| Total debt | $300.8 million | $300.8 million |
Revenue rose 3% (2% excluding favorable currency effects); net income increased 12% and diluted EPS 14%. Gross margin improved 1.6 percentage points. Operating cash flow declined about 3%, primarily as inventory increased. Year-end cash exceeded debt by approximately $604.9 million. Working capital increased largely because the credit facility renewal reclassified debt as long-term. The new $700 million unsecured revolving facility matures in October 2018; $300 million was drawn at year-end, and the company reported compliance with its covenants.
FY2014 revenue growth reflected higher unit sales of flow generators, masks and accessories, partly offset by lower average selling prices. North and Latin American revenue fell 1% amid competitor activity and pricing pressure; international revenue grew 8% reported and 5% in constant currency. Flow generators generated $846.7 million, while masks and other accessories generated $708.3 million.
Fiscal Q4: Revenue was $415.2 million versus $414.6 million a year earlier; gross profit was $261.3 million versus $259.8 million; net income was $87.7 million versus $73.0 million; diluted EPS was $0.61 versus $0.50. These figures indicate nearly flat Q4 revenue but stronger year-over-year earnings.
Changes, capital allocation and unusual items
- Gross-margin improvement was attributed to manufacturing and supply-chain savings, favorable product and geographic mix, and currency effects, partly offset by price declines.
- SG&A increased 5% to $450.4 million, reflecting staffing, market-awareness spending and patent litigation costs. R&D was $118.2 million, about 8% of revenue; reported spending fell 2%, but rose 6% in constant currency.
- FY2014 included $6.3 million of restructuring expense after a reorganization that eliminated about 1% of employees. FY2013 included a $24.8 million University of Sydney education, research and settlement charge, making the prior-year comparison unusual.
- ResMed repurchased 4.4 million shares for $208.1 million and paid $141.5 million in dividends. It announced an increase in the quarterly dividend from $0.25 to $0.28 per share in July 2014 and authorized a new repurchase program for up to 20 million shares.
- Most cash was held by foreign subsidiaries and considered permanently reinvested. Undistributed foreign earnings were about $1.5 billion; the company estimated that recognizing U.S. and withholding taxes on those earnings would require approximately $344 million.
Outlook, risks and contingencies
The filing gives no quantified revenue, earnings or margin guidance. Management described growth opportunities in connected/remote patient monitoring, home and hospital ventilation including COPD, and cardiology applications, while noting that demand in these areas depends in part on clinical-trial results and market adoption. New products introduced in 2014 included AirFit masks and the Astral life-support ventilator.
- Reimbursement and pricing: U.S. Medicare competitive bidding reduced payment rates for CPAP and respiratory devices by an average of about 47% in the second round, effective July 2013. Further bidding and healthcare-policy changes may pressure customers, prices and sales. A 2.3% U.S. medical-device excise tax also applies to certain products.
- Commercial and operational risks: Competition, customer/dealer consolidation, lower selling prices, reliance on some single-source suppliers, manufacturing disruption, international currency movements and longer domestic customer payment terms may affect results. Receivable days rose to 76 from 65; receivables increased 13% to $359.6 million.
- Regulatory and legal risks: Medical-device clearance, quality-system and post-market requirements can delay products or lead to recalls or penalties. Patent actions involving APEX and BMC were ongoing; management did not expect their outcomes to materially adversely affect consolidated financial statements, but litigation outcomes are uncertain.
- Other exposures: The company cited product-liability, intellectual-property, privacy/cybersecurity and tax-audit risks. It reported no significant off-balance-sheet arrangements. No goodwill impairment was identified, and the independent auditor issued unqualified opinions on the financial statements and internal control over financial reporting.
Important facts for investors to verify
- Confirm the intended period: this is FY2014, with separate FY2014 Q4 data, despite the request metadata referring to 2013 Q4.
- Track reimbursement and competitive-bidding effects, especially their impact on pricing, dealer health and U.S. revenue.
- Assess whether international growth and the gross-margin gains can offset North American softness and ongoing average selling price declines.
- Monitor working-capital conversion, including receivables aging and inventory growth, alongside operating cash flow.
- Review foreign cash/reinvestment and tax assumptions, the $300 million variable-rate borrowing, dividend commitments and ongoing share repurchases.
- Follow clinical evidence and adoption for COPD ventilation and cardiology applications, and the status and potential costs of the APEX and BMC patent cases.